Show simple item record

dc.contributor.authorPretorius, Judey
dc.date.accessioned2011-04-08T13:26:59Z
dc.date.available2011-04-08T13:26:59Z
dc.date.issued2008
dc.identifier.urihttp://hdl.handle.net/10394/4127
dc.descriptionThesis (Ph.D. (Pharmaceutical Chemistry))--North-West University, Potchefstroom Campus, 2009.
dc.description.abstractThe adenosine A2A receptor has emerged as an attractive target for the treatment of Parkinson's disease (PD). Evidence suggests that antagonists of the A2A receptor (A2A antagonists) partially alleviate the symptoms of PD, prevent the development of motor complications and may also slow the underlying neurodegenerative process. It was recently reported that several members of the (E)-8-styrylcaffeine class of A2A antagonists also are potent inhibitors of monoamine oxidase B (MAO-B).
dc.publisherNorth-West University
dc.titleThe synthesis and evaluation of caffeine analogues as inhibitors of monoamine oxidase B and antagonists of the adenosine A₂A receptoren
dc.typeThesisen
dc.description.thesistypeDoctoral


Files in this item

Thumbnail

This item appears in the following Collection(s)

  • ETD@PUK [6358]
    This collection contains the original digitized versions of research conducted at the North-West University (Potchefstroom Campus)

Show simple item record